- Home
- IRMD
IRMD
iRadimed Corporation
as of 03-12-2026 2:25pm EST
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
| Founded: | 1992 | Country: | United States |
| Employees: | N/A | City: | ORLANDO |
| Market Cap: | 1.3B | IPO Year: | 2014 |
| Target Price: | N/A | AVG Volume (30 days): | 44.8K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | Dividend Payout Frequency: | annual | |
| EPS: | 1.75 | EPS Growth: | 16.67 |
| 52 Week Low/High: | $47.48 - $107.90 | Next Earning Date: | 05-08-2026 |
| Revenue: | $83,814,000 | Revenue Growth: | 14.43% |
| Revenue Growth (this year): | 11.99% | Revenue Growth (next year): | 9.91% |
| P/E Ratio: | 57.61 | Index: | N/A |
| Free Cash Flow: | 17.2M | FCF Growth: | -2.48% |
Stock Insider Trading Activity of iRadimed Corporation (IRMD)
CEO, PRESIDENT, CHAIRMAN
Avg Cost/Share
$100.11
Shares
2,500
Total Value
$250,275.00
Owned After
2,247,500
SEC Form 4
CEO, PRESIDENT, CHAIRMAN
Avg Cost/Share
$100.04
Shares
5,000
Total Value
$500,200.00
Owned After
2,247,500
SEC Form 4
CEO, PRESIDENT, CHAIRMAN
Avg Cost/Share
$98.69
Shares
7,500
Total Value
$737,919.00
Owned After
2,247,500
Director
Avg Cost/Share
$100.26
Shares
1,000
Total Value
$100,256.30
Owned After
21,000
SEC Form 4
CEO, PRESIDENT, CHAIRMAN
Avg Cost/Share
$100.96
Shares
5,000
Total Value
$503,255.24
Owned After
2,247,500
CEO, PRESIDENT, CHAIRMAN
Avg Cost/Share
$101.92
Shares
5,000
Total Value
$509,224.99
Owned After
2,247,500
CEO, PRESIDENT, CHAIRMAN
Avg Cost/Share
$97.79
Shares
5,000
Total Value
$487,230.64
Owned After
2,247,500
CEO, PRESIDENT, CHAIRMAN
Avg Cost/Share
$97.22
Shares
5,000
Total Value
$488,417.26
Owned After
2,247,500
CEO, PRESIDENT, CHAIRMAN
Avg Cost/Share
$97.98
Shares
5,000
Total Value
$488,316.66
Owned After
2,247,500
CEO, PRESIDENT, CHAIRMAN
Avg Cost/Share
$97.06
Shares
5,000
Total Value
$483,671.84
Owned After
2,247,500
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Susi Roger E. | IRMD | CEO, PRESIDENT, CHAIRMAN | Mar 10, 2026 | Sell | $100.11 | 2,500 | $250,275.00 | 2,247,500 | |
| Susi Roger E. | IRMD | CEO, PRESIDENT, CHAIRMAN | Mar 9, 2026 | Sell | $100.04 | 5,000 | $500,200.00 | 2,247,500 | |
| Susi Roger E. | IRMD | CEO, PRESIDENT, CHAIRMAN | Mar 6, 2026 | Sell | $98.69 | 7,500 | $737,919.00 | 2,247,500 | |
| ALLEN MONTY K | IRMD | Director | Feb 13, 2026 | Sell | $100.26 | 1,000 | $100,256.30 | 21,000 | |
| Susi Roger E. | IRMD | CEO, PRESIDENT, CHAIRMAN | Jan 26, 2026 | Sell | $100.96 | 5,000 | $503,255.24 | 2,247,500 | |
| Susi Roger E. | IRMD | CEO, PRESIDENT, CHAIRMAN | Jan 20, 2026 | Sell | $101.92 | 5,000 | $509,224.99 | 2,247,500 | |
| Susi Roger E. | IRMD | CEO, PRESIDENT, CHAIRMAN | Jan 12, 2026 | Sell | $97.79 | 5,000 | $487,230.64 | 2,247,500 | |
| Susi Roger E. | IRMD | CEO, PRESIDENT, CHAIRMAN | Jan 5, 2026 | Sell | $97.22 | 5,000 | $488,417.26 | 2,247,500 | |
| Susi Roger E. | IRMD | CEO, PRESIDENT, CHAIRMAN | Dec 29, 2025 | Sell | $97.98 | 5,000 | $488,316.66 | 2,247,500 | |
| Susi Roger E. | IRMD | CEO, PRESIDENT, CHAIRMAN | Dec 22, 2025 | Sell | $97.06 | 5,000 | $483,671.84 | 2,247,500 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 10, 2026 · 100% conf.
Q4 2025 Earnings
8-K BUYFeb 10, 2026 · 100% conf.
1D
+0.53%
$105.71
5D
+4.46%
$109.84
20D
+6.22%
$111.69
IRADIMED CORPORATION_February 10, 2026 0001325618false00013256182026-02-102026-02-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE Date of report (Date of earliest event reported): February 10, 2026
IRADIMED CORPORATION
(Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation)
001-36534 73-1408526
(Commission File Number)
(IRS Employer Identification No.)
12705 Ingenuity Drive, Orlando, Florida 32826
(Address of principal executive offices)
(Zip Code)
(407) 677-8022 (Registrant’s telephone number, including area code) (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Securities registered pursuant to Section 12(b) of the Act:
Title of each class: Trading Symbol Name of each exchange on which registered:
Common stock, par value $0.0001
IRMD
NASDAQ Global Market
Item 2.02Results of Operations and Financial Condition. On February 10, 2026, IRADIMED CORPORATION issued a press release (the “Press Release”) announcing its financial results for the quarter ended December 31, 2025. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that Section. Furthermore, such information, including Exhibit 99.1, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01Financial Statements and Exhibits. (d) Exhibits
Exhibit No. Description
99.1 Press release dated February 10, 2026.
104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
IRADIMED CORPORATION
Date: February 10, 2026
By: /s/John Glenn
Name: John Glenn
Title: Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K Nov 3, 2025
Q3 2025 Earnings
8-KNov 3, 2025
IRADIMED CORPORATION_November 3, 2025 0001325618false00013256182025-11-032025-11-03
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE Date of report (Date of earliest event reported): November 3, 2025
IRADIMED CORPORATION
(Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation)
001-36534
73-1408526
(Commission File Number)
(IRS Employer Identification No.)
12705 Ingenuity Drive, Orlando, Florida
32826
(Address of principal executive offices)
(Zip Code)
(407) 677-8022 (Registrant’s telephone number, including area code) (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Securities registered pursuant to Section 12(b) of the Act:
Title of each class:
Trading Symbol
Name of each exchange on which registered:
Common stock, par value $0.0001
IRMD
NASDAQ Global Market
Item 2.02Results of Operations and Financial Condition. On November 3, 2025, IRADIMED CORPORATION issued a press release (the “Press Release”) announcing its financial results for the quarter ended September 30, 2025. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that Section. Furthermore, such information, including Exhibit 99.1, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01Financial Statements and Exhibits. (d) Exhibits
Exhibit No. Description
99.1 Press release dated November 3, 2025.
104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
IRADIMED CORPORATION
Date: November 3, 2025
By: /s/John Glenn
Name: John Glenn
Title: Chief Financial Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 1, 2025
Q2 2025 Earnings
8-KAug 1, 2025
0001325618false00013256182025-08-012025-08-01
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE Date of report (Date of earliest event reported): August 1, 2025
IRADIMED CORPORATION
(Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation)
001-36534
73-1408526
(Commission File Number)
(IRS Employer Identification No.)
12705 Ingenuity Drive, Orlando, Florida
32826
(Address of principal executive offices)
(Zip Code)
(407) 677-8022 (Registrant’s telephone number, including area code) (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Securities registered pursuant to Section 12(b) of the Act:
Title of each class:
Trading Symbol
Name of each exchange on which registered:
Common stock, par value $0.0001
IRMD
NASDAQ Global Market
Item 2.02Results of Operations and Financial Condition. On August 1, 2025, IRADIMED CORPORATION issued a press release (the “Press Release”) announcing its financial results for the quarter ended June 30, 2025. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that Section. Furthermore, such information, including Exhibit 99.1, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01Financial Statements and Exhibits. (d) Exhibits
Exhibit No. Description
99.1 Press release dated August 1, 2025.
104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
IRADIMED CORPORATION
Date: August 1, 2025
By: /s/John Glenn
Name: John Glenn
Title: Chief Financial Officer
Compare IRMD vs Leading Stocks
See how IRMD stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "IRMD iRadimed Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.